TSS
DSGN icon

Two Sigma Securities’s Design Therapeutics DSGN Stock Holding History

Two Sigma Securities’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,396
Closed -$107K – 1762
2025
Q4 		$107K Buy
+11,396
New +$89.2K 0.01% 967

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Securities's DSGN Position: Q1 2026 in Review

Two Sigma Securities sold out of Design Therapeutics (DSGN) in Q1 2026, closing a stake of 11,396 shares — an estimated $107K sold.

Two Sigma Securities first reported a position in DSGN in Q4 2025 and held it in 1 quarter. The position peaked at $107K in Q4 2025. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Two Sigma Securities reported no remaining Design Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Securities sold 11,396 Design Therapeutics shares in Q1 2026, an estimated $107K.
  • Two Sigma Securities first reported a position in Design Therapeutics in Q4 2025 and held it in 1 quarter.
  • Two Sigma Securities's Design Therapeutics position peaked at $107K in Q4 2025.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.